Research News

Crack GPAT — Prepare for GPAT Online 
  • New Drug to Prevent Migraine May Start Working Right Away
    27 December 2024

    New Drug to Prevent Migraine May Start Working Right Away

    A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology. The study looked at the drug atogepant, which is a calcitonin gene-related peptide CGRP receptor antagonist taken by mouth.
  • 27 December 2024
    Microtech Announces First Human Case of Implantable Microsensor for Heart Failure

    Microtech, a wholly owned subsidiary of Medinol Inc., a leader in global MedTech research and development, announced that it has initiated human clinical trials of their microsensor platform, in a trial to measure atrial pressures important for the treatment of heart failure. The first implantation was recently performed by Prof. Erez Sharoni at Beilinson Medical Center in Petah-Tikva, Israel.

  • 18 December 2024
    New drug shows promise against Duchenne muscular dystrophy
    A novel drug holds promise for treating Duchenne muscular dystrophy, a rare genetic disorder that causes severe muscle degeneration. McGill University researchers have discovered that an experimental compound called K884 can boost the natural repair abilities of muscle stem cells. Current treatments can slow muscle damage, but don’t address the root problem.
  • 18 December 2024
    UW researchers find previously unknown links between microbial bile acids and the risk of colon cancer

    In many ways, that relationship revolves around a specific protein called the farnesoid X receptor, or FXR, which helps maintain a healthy gut through its intimate relationship with bile acids. FXR controls the production of bile acids in the liver, but it also responds in different ways to the presence of various bile acids that microbes have modified.  

  • 18 December 2024
    Unlocking the Brain : Peptide-Guided Nanoparticles Deliver mRNA to Neurons
    Penn Engineers have modified lipid nanoparticles the revolutionary technology behind the COVID-19 mRNA vaccines to not only cross the blood-brain barrier but also to target specific types of cells, including neurons. This breakthrough marks a significant step toward potential next-generation treatments for neurological diseases like Alzheimer’s and Parkinsons.
  • 16 December 2024
    Activating the hidden pharmaceutical potential of bacteria

    Researchers develop a new genetic method for the production of new active ingredients in bacteria

  • 16 December 2024
    Researchers describe a potential target to address a severe heart disease in diabetic patients
    Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders. This often under-diagnosed heart function impairment is one of the leading causes of death in diabetic patients and it affects both type 1 and type 2 diabetes. There is no current specific drug treatment or clinical protocol approved to address this disease.
  • 16 December 2024
    A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth : study finds

    A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators offers new evidence that dietary changes may help reduce cancer cell growth in patients undergoing active surveillance, a treatment approach that involves regular monitoring of the cancer without immediate intervention.

  • 13 December 2024
    Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
    Updated results from the OlympiA Phase III trial showed AstraZeneca and MSDs Lynparza olaparib demonstrated sustained, clinically meaningful improvements in overall survival , invasive disease-free survival IDFS and distant disease-free survival DDFS at six years for patients with germline BRCA-mutated gBRCAm HER2-negative high-risk early breast cancer.
  • 13 December 2024
    Antidepressants may act in gut to reduce depression and anxiety

    Most of us have experienced the effects of moods and emotions on our gastrointestinal tract, from “butterflies” in the stomach caused by nervousness to a loss of appetite when we’re feeling blue.

Subscribe to Research News